NCIt definition : An orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like
kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration,
onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces
selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor
cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine
kinase that is crucial for the regulation of mitosis, and plays a key role in tumor
cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types
and high expression is associated with increased aggressiveness and poor prognosis.;
UNII : 67RM91WDHQ;
InChIKey : QHLVBNKYJGBCQJ-UHFFFAOYSA-N;
CAS number : 1034616-18-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1034616-18-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;